

% uptake per 10^8 cells+/- ${
m SD}$




FIG. 3A

FIG. 3B



FIG. 4A



FIG. 4B

Doxorubicin-treated tumors

Non-treated





FIG. 5A


FIG. 50



%ID\8

Tumor/ Kidney 0.86 0.59 Tumor/ Heart 1.07 5.69 Tumor/ Liver 0.88 4.68 Tumor/ Liver 0.88 4.68 Tumor/ Muscle 1.61 8.66 Tumor/ Fast tissue 6.60 5.20 Tumor/ Spleen 2.42 3.86 Tumor/ Lung 1.07 2.52 Tumor/ Blood 1.43 3.50 Tumor/Small inte stine 1.18 2.26 Tumor Tumor 1.18 2.26		Control	Doxo (2x20 mg/ kg)
1.07 ile 0.88 0.88 issue 6.60 intestine 1.43 0.07	Tumor/ Kidney	0.86	0.59
1.61 tissue 6.60 c.42 d 1.43 d 1.18 c.07	Tumor/ Heart	1.07	5.69
6.60 6.60 1.07 1.43 1.18 0.07	Tumor/ Liver	0.88	4.68
6.60 2.42 1.07 1.43 4ine 1.18	Tumor/ Muscle	1.61	8.66
2.42 1.07 1.43 nte stine 1.18	Tumor/ Fast tissue	09'9	5.20
1.07 1.43 inte stine 1.18	Tumor/ Spleen	2.42	3.86
1.43 Inte stine 1.18 0.07	Tumor/ Lung	1.07	2.52
1.18	Tumor/ Blood	1.43	3.50
0.07	Tumor/Small inte stine		2.26
	Tumor	0.07	1.28

FIG. 7




10/13



=1G.9B



=1G. 9A



WO 2005/067388 PCT/IL2005/000055

12/13

